Fig. 8

KIFC1 inhibition enhances HCC cell sensitivity to paclitaxel. a and b Growth curves depicted from the CCK-8 assay revealed cell vitality following treatment with paclitaxel and sorafenib. Paclitaxel was tested in KIFC1-knockdown 7701 and 7402 cells and KIFC1-overexpressing HepG2 cells. Sorafenib was examined in KIFC1-knockdown 7701 and 7402 cells. c and d Clone formation and Transwell invasion assays were tested with or without paclitaxel in the indicated cells. The counts of clone and invaded cell numbers are shown in the right panels. Data are presented as the mean ± SD, * P < 0.01, ** P < 0.001